LA Improves the Prognosis of Patients With ICVD
Ischemia, Cerebrovascular Ischemia, Cognitive Impairment

About this trial
This is an interventional treatment trial for Ischemia
Eligibility Criteria
Inclusion Criteria: Between 35 and 65 years old; Han nationality; Diagnosed as ischemic cerebrovascular disease with mild to moderate symptoms; Can communicate normally, complete neuropsychological tests independently, and sign informed consent; No previous surgical history; No contraindications such as PET, MRI and DSA; No history of stroke identified by imaging; No family history of other chronic diseases, cancer, mental illness or dementia; Improved Rankin scale score ≤2; Ischemic symptoms appeared in the carotid area ≤3 months before the visit; In line with the surgical treatment of ischemic cerebrovascular disease; Exclusion Criteria: previous dementia; hearing or visual impairment; Drugs that may or are known to influence cognitive abuse; alcohol addiction; Diagnosis of depression, schizophrenia and other psychiatric diseases; MRI showed severe cerebral infarction; Those allergic to Lactobacillus acidophilus; Baseline CT showed intracranial hemorrhage; ischemic onset accompanied by epilepsy; illiteracy; pregnancy or breastfeeding; any serious medical condition that may interact with treatment;
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Control group
LA treatment group
The patient received conventional treatment and Maltodextrin treatment (placebo) for three months after surgery.
The patient received conventional treatment and Lactobacillus acidophilus treatment for three months after surgery.